LobbyingGlaxosmithkline Consumer Healthcare Holdings LLC Dba Haleon lobbying by quarter
Glaxosmithkline Consumer Healthcare Holdings LLC Dba Haleon's latest lobbying report covers Q4 2023, at $180K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Taxation/Internal Revenue Code.
Glaxosmithkline Consumer Healthcare Holdings LLC Dba Haleon
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $50K | 1 |
| Q1 2023 | $50K | 1 |
| Q2 2023 | $70K | 1 |
| Q3 2023 | $130K | 1 |
| Q4 2023 | $180K | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$291.7K · 5 reports
- Taxation$171.7K · 3 reports
- Budget and appropriations$16.7K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES5 reports
- SENATE5 reports
Firms it paid
| Firm | ||
|---|---|---|
| Venable | $480K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SAMUEL OLCHYK | Legislation Counsel, Joint Committee on Taxation; Tax Counsel, Senate Finance Committee | Q3 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/01/20for Q4 2023 | Venable | $180K |
| 23/10/20for Q3 2023 | Venable | $130K |
| 23/07/19for Q2 2023 | Venable | $70K |
| 23/04/19for Q1 2023 | Venable | $50K |
| 23/01/19for Q4 2022 | Venable | $50K |